Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

NCT05201404 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

471

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma
Cirrhosis

Interventions

DRUG: Namodenoson
DRUG: Placebo

Sponsor

Can-Fite BioPharma